Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thr… Read more
Market Cap & Net Worth: Kissei Pharmaceutical Co. Ltd (KSPHF)
Kissei Pharmaceutical Co. Ltd (PINK:KSPHF) has a market capitalization of $988.64 Million ($988.64 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #8951 globally and #4412 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kissei Pharmaceutical Co. Ltd's stock price $23.85 by its total outstanding shares 41452593 (41.45 Million).
Kissei Pharmaceutical Co. Ltd Market Cap History: 2017 to 2025
Kissei Pharmaceutical Co. Ltd's market capitalization history from 2017 to 2025. Data shows change from $1.11 Billion to $988.64 Million (-1.02% CAGR).
Kissei Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kissei Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Kissei Pharmaceutical Co. Ltd's market cap is 0.01 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.08x
Kissei Pharmaceutical Co. Ltd's market cap is 0.08 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.11 Billion | $643.52 Million | $69.34 Million | 1.72x | 15.94x |
| 2018 | $1.14 Billion | $695.80 Million | $85.06 Million | 1.64x | 13.38x |
| 2019 | $1.13 Billion | $653.22 Million | $49.52 Million | 1.74x | 22.90x |
| 2020 | $875.29 Million | $585.85 Million | $26.09 Million | 1.49x | 33.54x |
| 2021 | $780.46 Million | $69.04 Billion | $5.29 Billion | 0.01x | 0.15x |
| 2022 | $740.02 Million | $65.38 Billion | $12.92 Billion | 0.01x | 0.06x |
| 2023 | $854.21 Million | $67.49 Billion | $10.53 Billion | 0.01x | 0.08x |
| 2024 | $1.04 Billion | $75.58 Billion | $11.16 Billion | 0.01x | 0.09x |
| 2025 | $988.64 Million | $88.33 Billion | $11.96 Billion | 0.01x | 0.08x |
Competitor Companies of KSPHF by Market Capitalization
Companies near Kissei Pharmaceutical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Kissei Pharmaceutical Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kissei Pharmaceutical Co. Ltd Historical Marketcap From 2017 to 2025
Between 2017 and today, Kissei Pharmaceutical Co. Ltd's market cap moved from $1.11 Billion to $ 988.64 Million, with a yearly change of -1.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $988.64 Million | -4.60% |
| 2024 | $1.04 Billion | +21.32% |
| 2023 | $854.21 Million | +15.43% |
| 2022 | $740.02 Million | -5.18% |
| 2021 | $780.46 Million | -10.83% |
| 2020 | $875.29 Million | -22.81% |
| 2019 | $1.13 Billion | -0.35% |
| 2018 | $1.14 Billion | +2.95% |
| 2017 | $1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kissei Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $988.64 Million USD |
| MoneyControl | $988.64 Million USD |
| MarketWatch | $988.64 Million USD |
| marketcap.company | $988.64 Million USD |
| Reuters | $988.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.